← Back to Clinical Trials
Recruiting NCT06963489

NCT06963489 Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06963489
Status Recruiting
Phase
Sponsor First Affiliated Hospital of Wannan Medical College
Condition Large Vessel Occlusion
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2025-04-27
Primary Completion 2028-02-29

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Not applicable- observational study

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2025-04-27 with a primary completion date of 2028-02-29.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This multicenter, ambispective cohort study establishes a comprehensive multiomics biobank from five stroke centers, encompassing thrombi, intracranial blood, peripheral arterial/venous blood, and clinical-laboratory-imaging-follow-up data from patients with acute ischemic stroke with large vessel occlusion (AIS-LVO).

Eligibility Criteria

Inclusion Criteria: 1. Age over 18 years. 2. Patients with intracranial and extracranial large vessel occlusion ischemic stroke confirmed by cerebrovascular angiography. 3. Availability of complete clinical and follow-up information required for the study. 4. Availability of blood and/or thrombus biological samples. 5. Voluntary written informed consent signed by the patient or their family (1) For retrospectively enrolled patients, a "broad informed consent" was signed at the time of sample collection. Upon enrollment into the cohort, a follow-up phone call was made to confirm the informed consent. (2) For prospectively enrolled patients, informed consent for this study was signed at the time of enrollment by the patient or their family. Exclusion Criteria: 1. Patients for whom biological samples cannot be obtained; 2. Patients or their family members who refuse to sign the informed consent form.

Contact & Investigator

Central Contact

Zhiyuan Feng, MD

✉ fzyhhz1996@gmail.com

📞 86+15801290121

Frequently Asked Questions

Who can join the NCT06963489 clinical trial?

This trial is open to participants of all sexes, studying Large Vessel Occlusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06963489 currently recruiting?

Yes, NCT06963489 is actively recruiting participants. Contact the research team at fzyhhz1996@gmail.com for enrollment information.

Where is the NCT06963489 trial being conducted?

This trial is being conducted at Wuhu, China, Baotou, China, Jinan, China, Henan, China and 1 additional location.

Who is sponsoring the NCT06963489 clinical trial?

NCT06963489 is sponsored by First Affiliated Hospital of Wannan Medical College. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology